AVADEL PHARMACEUTICALS PLC
AVDL evidence brief
What we can confirm
- BioSniper Score:
- 5.9 / 10
- Market Cap:
- $2.12B
- Lead Asset:
- LUMRYZ (Phase 3)
What it means
What to watch
Prepared research question
What matters most for AVDL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 1 pipeline candidate · 2 clinical trials for AVADEL PHARMACEUTICALS PLC.
Run AVADEL PHARMACEUTICALS PLC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AVADEL PHARMACEUTICALS PLC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is AVADEL PHARMACEUTICALS PLC's lead drug candidate?
AVADEL PHARMACEUTICALS PLC's most advanced tracked candidate is LUMRYZ (Phase 3) for Narcolepsy.
Who is the CEO of AVADEL PHARMACEUTICALS PLC?
Chief Executive Officer is the chief executive officer of AVADEL PHARMACEUTICALS PLC (AVDL).
Where is AVADEL PHARMACEUTICALS PLC headquartered?
AVADEL PHARMACEUTICALS PLC (AVDL) is headquartered in Dublin, Ireland.
What therapeutic areas does AVADEL PHARMACEUTICALS PLC focus on?
AVADEL PHARMACEUTICALS PLC develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.